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Summary
Diabetes mellitus and osteoporosis are two frequent multifac-
torial medical conditions with an increasing prevalence in the
aging population. Patients with type 2 diabetes mellitus have
an increased fracture risk despite a higher bone mineral den-
sity (BMD), which is mainly due to the increased risk of falls.
Adequate glycemic control and prevention of diabetic compli-
cations are also the mainstay of therapy in type 2 diabetes
mellitus. The thiazolidinediones (TZDs) have been demon-
strated to improve insulin sensitivity and currently represent a
widely prescribed treatment for type 2 diabetes. Their action is
mediated by the binding to the nuclear receptor and transcrip-
tion factor, peroxisome proliferator-activated receptor-γ
(PPAR-γ), regulating the activity of other transcription factors
in the adipogenic differentiation and inflammatory response
pathways. The activation of PPAR-γ by TZDs may also cause
an increase in bone marrow adiposity and a decrease in os-
teoblastogenesis, resulting in reduced bone formation. Clini-
cal data are pointing out that the intake of thiazolidinediones
by older patients with type 2 diabetes correlates with both the
decrease of bone mineral density in the femoral neck and hip
and a higher risk for fractures. Thus, health care providers,
not only physicians, should carefully check the existence of
risk factors for osteoporosis and factures in their patients be-
fore selecting them for thiazolidinediones treatment. More-
over, an adequate clinical follow-up of treated subjects is
strongly recommended.
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Introduction
Type 2 Diabetes Mellitus (T2DM) is characterized by peripheral
insulin resistance with a variable degree of hyperinsulinemia
and impaired insulin secretion following metabolic challenge by
glucose. Long standing hyperglycemia leads to non-enzymatic
glycosylation of various bone proteins, including type I colla-
gen, which may impair the bone quality. Other skeletal effects
of hyperglycemia are represented by glycosuria-related hyper-
calciuria and perturbation of the PTH (parathyroid hormone)/vi-
tamin D axis. 
In 1980, a large retrospective study described that diabetes
was not associated with increased risk of fracture except at the
ankle level (1). In T2DM females, Bonds et al. reported an
overall risk of fracture higher in subjects with diabetes at base-
line, also considering their higher frequency of falls (2). In fact,
a recent review reported that women with T2DM, despite a
higher bone mineral density (BMD), display a 1.7-fold in-
creased hip fracture risk, which is mainly attributable to the in-
creased risk of falling, as also previously assessed by the Rot-
terdam Study (3).
Interestingly, the adverse effects of hyperglycemia on the
skeleton are largely counteracted by the positive effects of obe-
sity on BMD. In fact, it has been suggested that obesity may
protect against bone loss according to the findings that BMD
and body mass index (BMI) are positively correlated in patients
with T2DM (4, 5) and that the BMI in these patients negatively
associates with the presence of osteoporosis (6).
Moreover, it has been reported that axial BMD negatively cor-
relates with the duration of T2DM (7), whereas cortical BMD
negatively associates with mean hemoglobin A1c (HbA1c)
serum levels, an index of poor metabolic control (7).
Adipose tissue produces peculiar cytokines, namely
adipokines, such as leptin, resistin, and adiponectin, that may
modulate the BMD increases. Recently, an inverse association
between adiponectin serum levels and BMD, at different skele-
tal sites, has been reported in patients with T2DM (8).
Thiazolidinediones (TZDs) are ligands for peroxisome prolifera-
tor activated receptor-γ (PPAR-γ), a family of nuclear receptors
able to regulate gene transcription. PPAR-γs expression is par-
ticularly abundant in adipocytes in which they regulate differen-
tiation and function. A lower expression of PPAR-γs has been
reported in pancreatic islet cells, liver, skeletal muscle, vascu-
lar endothelium, and bone.
TZDs have been considered an elective treatment for diabetes
increasing insulin sensitivity through activation of PPAR-γ path-
way. It is known that activation of PPAR-γ improves glucose
metabolism by enhancing tissue sensitivity to insulin, primarily
through its action on adipose cells.
However, early studies suggested that TZDs were no more
effective in lowering glycemia than older oral medications (9).
These findings, the previously reported side effects of the
TZDs (such as weight gain, fluid retention, and the risk of
congestive heart failure) and the higher cost of brand-name
TZDs than that of generic metformin, determined a reconsid-
eration of their line positioning in the choice of treatment of
diabetes (10).
Rosiglitazone and pioglitazone are currently the commercially
available TZDs for therapeutical purposes. It has been reported
that during 2005, in the USA, they have been prescribed over
22 million times (http://www.diabetesdaily.com/forum/research-
clinical-trials/3480-tzds-broken-bones). Both drugs have been
shown to reduce either glycemia or HbA1c through an increase
sensitivity to insulin through the lowering of insulin resistance.
However, considering the relationships between glycemic ben-
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efit of rosiglitazone, its related risk of fluid retention and weight
gain, and its higher cost, also due to the need for more statins
and diuretics, metformin could be still considered the preferred
first choice in the pharmacotherapy for T2DM (11).
Major pitfalls in the clinical use of TZDs: not only 
hepatotoxicity
Several adverse effects of TZDs have been emerging from the
postmarket analyses. In 2000, Parke-Davis/Warner Lambert
agreed to the FDA’s request to withdraw its TZD, called trogli-
tazone (Rezulin), from the market because of severe hepato-
toxicity (http://www.fda.gov/bbs/topics/news/new00721.html).
In fact, troglitazone was found to be more toxic to the liver than
rosiglitazone and pioglitazone. 
TZDs have been also implicated in causing edema (12).
TZDs: are they osteotoxic?
In vitro and animal studies
Effects on osteoblasts 
It has been reported that activation of PPAR-γ by TZDs may
cause an increase in bone marrow adiposity and a decrease in
osteoblastogenesis, resulting in reduced bone formation (13).
TZDs may exert their effects on enhanced insulin sensitivity
through the regulation of adiponectin secretion by fat cells (14).
Indeed, receptors for adiponectin have been demonstrated in
bone, and in vitro studies suggested that adiponectin is able to
stimulate osteoblast differentiation (15, 16). Although the exact
mechanism is still unclear, it is thought that its agonistic activity
to PPAR-γ may promote the differentiation of precursor cells in-
to adipocytes instead of transforming them into osteoblasts, in-
fluencing also the lineage allocation of mesenchymal stem
cells (MSC) in the bone marrow. Indeed rosiglitazone exhibits
all these actions.
As a consequence, TZDs are reported to cause bone loss in
some rodent models (13, 17-19), but not in all (19). Interesting-
ly, in mice the haploinsufficiency of the PPAR-γ gene induces a
high bone density phenotype with an increased rate of os-
teoblastic bone formation (20, 21), whereas a deficient os-
teoblast function and a consequent bone loss have been re-
ported in rodents treated with PPAR-γ agonists (13, 20, 21). In
animal models, this observation was particularly true in ovarec-
tomized rats, but not in male animals (http://www.diabetesdai-
ly.com/forum/research-clinical-trials/3480-tzds-broken-ones). 
Overall, in the rodent models, rosiglitazone treatment decreas-
es osteoblast function and increases bone loss (13, 17, 22). In
addition to bone loss, in the animal models rosiglitazone treat-
ment results in greater marrow adiposity (13, 22).
Effects on osteoclasts
The effect of PPAR-γ activation on osteoclasts has not been
clearly established. Some animal models did not exhibit a dif-
ferent resorption function (13, 17, 22), but others were found to
show an increased bone resorption (18). Through a co-culture
system approach, Okazaki et al. (23) and Mbalaviele et al. (24)
demonstrated that specific PPAR-γ agonists, including the not
commercially available compound ciglitazone, cause a dose-
dependent blockage of osteoclast formation and resorption.
Recently, activation of individual PPARs with isoform-specific
agonist resulted in significant dose-dependent inhibition of
multinucleated osteoclast formation. In particular, ciglitazone
and L165041 compounds resulted respectively to inhibit and to
stimulate osteoclastic function. Thus, isoform-specific PPAR
agonists may play strong effects on multinucleation with vari-
able effects on bone resorption (25). 
Although the exact mechanism behind this inhibition of osteo-
clast formation and resorption has not yet been determined, it is
known that PPAR-γ is able to antagonize the transcription factor
NF-κB (26) which is the fundamental pathway for RANKL sig-
naling and essential for osteoclast development, survival and
function (27).
No data are currently available on a possible role of TZDs on
osteocytes.
Clinical findings in humans
TZDs and risk for bone fractures
Little information is available on the effects of TZDs on bone in
humans. The increased use of TZD treatment and the recog-
nized evidence that T2DM is associated with a higher risk of
fracture, represented important bases for investigation on the
possibility that TZDs can cause bone loss in humans. If this
was true, one should rethink their therapeutical use, at least in
patients with an increased fracture risk. Unfortunately, due to
the fact that the use of TZDs in T2DM is relatively recent, only
few reports on TZD therapy and fracture risk are currently
available.
Interestingly, Asian women with a PPARγ polymorphism exhibit
a reduced bone mineral density (28) and lower circulating os-
teoprotegerin levels (29), suggesting a direct role of PPAR-γs in
bone metabolism. It has been suggested that the TZDs might
decrease bone turnover independently of their effects on glu-
cose metabolism, through a decreased bone-resorption, evalu-
ated by bone turnover markers assessment, in T2DM patients.
More definite findings are needed by independent studies as al-
so whether this effect will consists of an increase in bone miner-
al density and a decrease in fracture risk in T2DM patients.
In the study by Okazaki et al., on T2DM patients, it has been
also found that a 4 weeks troglitazone treatment reduced mark-
ers of bone turnover by 7-18% (23). Later, a small study on
troglitazone use reported that the bone mineral density Z-
scores at the lumbar spine was not changed after 12 months of
treatment in 25 diabetic patients. Moreover, bone turnover
markers levels, such as urinary type 1 collagen, N-telopeptide
and serum bone alkaline phosphatase, resulted reduced after
the first month of treatment, returning to baseline levels by 12
months (30).
On the contrary, more recent studies have reported that T2DM
individuals exhibited a higher risk for hip (31-38), proximal
humerus (33, 34), foot (33, 38), and all nonvertebral fractures
combined (33, 34, 36, 39).
Bone fractures in patients treated with TZDs involve “non clas-
sical” skeletal sites?
In a randomized, double blind parallel group study, named “A
Diabetes Outcome Progression Trial (ADOPT)”, the bone-relat-
ed adverse events associated with this drug use were de-
scribed (40). The trial, that compared glycemic control in pa-
tients taking rosiglitazone, metformin, or glyburide, involved
4360 patients aged 30 to 75 years with recently diagnosed
T2DM who were followed for 4 to 6 years. Only 30 subjects
had fractures in the metformin and 20 in the glyburide group,
with 60 patients fracturing in the rosiglitazone group. Fracture
risk was the same across groups in men, with higher incidence
in women taking rosiglitazone.
Fracture sites were considered “atypical” for postmenopausal
osteoporosis, that normally involves the spine and the hip, with
women in the rosiglitazone arm experiencing prevalent frac-
tures of the upper arm, hand, or foot when compared to the
other treatment arms.
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Data from the Nurses’ Health Study (41) suggests a 6-fold
higher risk of hip fracture in patients with type 1 diabetes melli-
tus and twice the risk in patients with T2DM. Other studies
demonstrated an increased risk of fractures of the hip,
humerus and foot in diabetic patients treated with insulin, with
no increase in vertebral fractures. Patients with diabetes are al-
so at higher risk for falls than non-diabetic patients (41).
In addition, recent clinical observations from the Health ABC
trial indicated a 2.5-fold accelerated bone loss in post-
menopausal diabetic women using TZDs, but not in men (22
patients taking troglitazone, 30 pioglitazone and 31 rosiglita-
zone), with an additional annual bone loss in older diabetic
women using any TZD lower (0.5% at the total hip and 1.2% at
the spine) (42). 
A recent randomized clinical trial from New Zealand demon-
strated that 8 mg of rosiglitazone daily decreases bone mass
and bone formation in 50 postmenopausal women without di-
abetes (43). The trial enrolled healthy postmenopausal
women who did not have diabetes or osteoporosis and after
14 wk of treatment with rosiglitazone, the subjects experi-
enced a significant decrease in bone density (-1.9% rosiglita-
zone vs. -0.2% placebo) at the total hip accompanied by a
modest reduction (-8 to -13%) in bone formation markers with-
out a change in resorption markers. No data are available on
the possibility that bone loss continues or bone density stabi-
lizes or even recovers (43). In an Editorial to this paper
Schwartz and Sellmeyer reported: “If the rate of bone loss
identified in this trial (43) continued for a year, the additional
loss with rosiglitazone therapy would be 6.8%, compared with
an average loss in postmenopausal women of about 1% an-
nually” (44). A criticism that can be moved to this trial is repre-
sented by both the short duration and the fact that a healthy
population was evaluated. Conversely, the latter issue can al-
so represent an advantage, allowing the assessment of
rosiglitazone side effects on bone metabolism, independently
on any other confounding factor (43).
Thus, these findings by Grey et al., clearly established the evi-
dence for a detrimental effect of PPAR-γ agonists on the post-
menopausal female skeleton (43). A randomized controlled trial
also in men will be necessary in order to define a gender differ-
ence in the skeletal response to TZDs.
Warnings from Pharmaceutical Companies 
and Institutions
The use of rosiglitazone and pioglitazone clearly showed “dan-
gerous effects” in some patients. Therefore, both the FDA and
Takeda Pharmaceuticals North America Inc, the manufacturer
of pioglitazone, notified health care professionals that clinical
trial data indicated that the female patients treated groups pi-
oglitazone exhibited more fractures than comparators (either
placebo or other drugs).
Takeda’s letter to clinicians noted that the fracture incidence
was 1.9 fractures per 100 patient-years in the pioglitazone
treated group compared with 1.1 fractures in the comparator-
treated groups (http://www.fda.gov/medwatch/safety/2007/
safety07.htm#Glycerin).
This translates in an excess risk of 0.8 fractures per 100 pa-
tient-years of use for women taking the drug. Further evalua-
tion of these findings is ongoing and the Company stated that
“none of the pioglitazone studies addressed, or were designed
to study, the effect on bone, but fractures were collected as ad-
verse events”.
The warning was sent out on 3/9/07 for pioglitazone, as in-
creased risk for fractures in the distal arms and legs was ob-
served in postmenopausal women.
The numbers and the unexpected fracture sites reported by
Takeda correspond well with observations for rosiglitazone.
The FDA posted a similar warning in February for the drug
rosiglitazone (http://www.fda.gov/medwatch/safety/2007/safe-
ty07.htm#rosiglitazone). At the manufacturer’s request, an in-
dependent Safety Committee reviewed fractures in another
large, ongoing, controlled trial, and a preliminary analysis was
consistent with the observations from ADOPT. 
Open questions
Common sense suggests the need to identify and minimize risk
factors for falls (advanced age, impaired balance, cardiovascu-
lar disease, neuropathy) in subjects with reduced BMD through
implementation of a program combining regular exercise, ade-
quate vitamin D supplementation, withdrawal of psychotropic
medications when possible, visual assessment, environmental
hazard assessment and modification, and the use of hip pro-
tectors. Although more basic and clinical research data will be
necessary to elucidate the relationship among TZDs therapy,
bone metabolism and risk fractures, some practical indications
are emerging.
What does this could represent in the daily clinical practice of
health care providers? 
It is mandatory to advice health care providers on the possibili-
ty of increased bone loss and fracture risk associated with
TZDs use. In fact, current data strongly suggest a higher risk
for adverse skeletal effects in middle-aged and older women.
An overall survey considering all the existing fractures risk in
the population of subjects to be treated has to anticipate the
choice of treatment.
Consequently, an accurate evaluation of the pre-existing pa-
tient’s fracture risk needs to be adequately performed in each
subject before prescribing TZD therapy. Adequate osteoporosis
therapy should be initiated in those women exhibiting a reduced
bone density and other risk factors for fracture at the baseline.
Additional studies are needed to ascertain the degree of bone
loss and fracture risk in postmenopausal women associated with
long-term TZD therapy and to identify whether TZDs have nega-
tive skeletal effects in men and premenopausal women.
It is obvious that all T2DM patients at risk should optimize nutri-
tion and lifestyle factors in any case to better protect skeletal
health, independently by the decision for a treatment with
TZDs.
How to correctly select patients you would not start on TZDs
and how to correctly recognize patients you would even take
off these drugs?
All the patients to be eventually treated by TZDs are strongly
recommended to undergo careful evaluation of both bone
mass and bone turnover markers at the beginning and periodi-
cally during therapy, in order to reduce the occurrence of frac-
tures, worsening the quality of life, and consequently their relat-
ed socio-economical costs. 
An accurate osteoporosis screening is strongly suggested also
for T2DM older men at baseline, evaluating possible causes of
secondary osteoporosis, such as pre-existing medical status or
drugs capable to induce bone loss.
However, since rosiglitazone may increase marrow fat, it has to
be considered that the extent and the rate of bone loss during
therapy may not be accurately assessed using the gold stan-
dard dual energy x-ray absorptiometry (DXA). Indeed, DXA
scans may suffer because of the artificial decreases in bone
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mineral density (BMD) associated to an increased marrow fat
(19, 45).
Of course, it should be recommended that physicians, who po-
tentially have to face such problems, must be adequately and
appropriately informed on both the correct management of
bone disorders and the correct interpretations of the new warn-
ings occurring in this field. 
Do these findings on bone fractures limit the potential benefi-
cial effects on glycemic control by TZDs?
Given the known benefits of TZD therapy for diabetes, the ben-
efits of therapy may still outweigh the side effects, particularly
in those with a low risk of fracture.
According to these findings it is clearly emerging the need of
keeping a close control on the TZDs’ potential dangers for both
study participants and diabetic patients in the general popula-
tion.
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